Live
FierceBiotechChutes & Ladders—Eric Topol boards Flagship as advisorFierceBiotechBehind the curtain: What Xaira is building after its $1B fundraiseFierceBiotechIntuitive recalls surgical stapler reloads following patient deathAgilentAgilent Brings Expanded PD-L1 Testing and Digital Pathology Workflows to USCAP 2026 - Clinical Lab ProductsBioPharma DiveRoche stops work on experimental SMA drugEndpoints NewsSarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesityEndpoints NewsChina-rooted AI biotech Earendil Labs raises $787M ahead of possible IPOEndpoints NewsUK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing thresholdBioPharma DiveNovartis pays $2B to land a startup’s breast cancer drugAgilentAgilent Debuts Future of the Automated Laboratory at Korea Lab 2026 - marketscreener.comPharmaVoiceGilead could potentially end HIV. But will it be able to?BioWorldTreeline Biosciences reports TEAD degraders
eLife Jan 22, 2026

A titin missense variant drives atrial electrical remodeling and is associated with atrial fibrillation

A titin missense variant drives atrial electrical remodeling and is associated with atrial fibrillation

Original
Body unavailable. Use the original source.

Directory

59 All